Log in to save to my catalogue

DFV890: a new oral NLRP3 inhibitor—tested in an early phase 2a randomised clinical trial in patients...

DFV890: a new oral NLRP3 inhibitor—tested in an early phase 2a randomised clinical trial in patients...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9473473

DFV890: a new oral NLRP3 inhibitor—tested in an early phase 2a randomised clinical trial in patients with COVID-19 pneumonia and impaired respiratory function

About this item

Full title

DFV890: a new oral NLRP3 inhibitor—tested in an early phase 2a randomised clinical trial in patients with COVID-19 pneumonia and impaired respiratory function

Publisher

Berlin/Heidelberg: Springer Berlin Heidelberg

Journal title

Infection, 2023-06, Vol.51 (3), p.641-654

Language

English

Formats

Publication information

Publisher

Berlin/Heidelberg: Springer Berlin Heidelberg

More information

Scope and Contents

Contents

Background
Coronavirus-associated acute respiratory distress syndrome (CARDS) has limited effective therapy to date. NLRP3 inflammasome activation induced by SARS-CoV-2 in COVID-19 contributes to cytokine storm.
Methods
This randomised, multinational study enrolled hospitalised patients (18–80 years) with COVID-19-associated pneumonia and...

Alternative Titles

Full title

DFV890: a new oral NLRP3 inhibitor—tested in an early phase 2a randomised clinical trial in patients with COVID-19 pneumonia and impaired respiratory function

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9473473

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9473473

Other Identifiers

ISSN

0300-8126

E-ISSN

1439-0973

DOI

10.1007/s15010-022-01904-w

How to access this item